ADVERTISEMENT
ADVERTISEMENT

Falla autonómica asociada a hipoglucemia

Solange Leda Houssay, Maricel Recalde, Marcela Giménez Rey, Concepción García, Raquel Urdaneta, Fernanda Huber, Claudia Flores, Carolina Domínguez, Emilio Nader

Resumen


La hipoglucemia inadvertida (HI) es una complicación del tratamiento de la diabetes mellitus tipo 1 (DM1) y DM2 tratada con insulina o sulfonilureas, que se caracteriza por una capacidad reducida para percibir el inicio de los episodios de hipoglucemia. En general, coexiste con una insuficiente respuesta hormonal contrarreguladora a la hipoglucemia denominada falla autonómica asociada a la hipoglucemia (FAAH). El desarrollo de HI y de falla contrarreguladora a la hipoglucemia aumentan significativamente el riesgo de hipoglucemias severas. Se han desarrollado escalas de puntuación para identificar, en la consulta clínica, a este grupo de personas con elevado riesgo de hipoglucemias severas. La piedra angular del tratamiento consiste en evitar las hipoglucemias mediante una intervención multifactorial de cuidados clínicos y educación estructurada.

 


Palabras clave


hipoglucemia inadvertida; falla autonómica asociada a la hipoglucemia; hipoglucemia severa; diagnóstico, tratamiento.

Texto completo:

PDF

Referencias


I. Joslin E, Gray H, Root H. Insulin in hospital and home. J Metab Res 1922; 2:651-99.

II. Clarke W, Cox D, Gonder-Frederick L, Julian D, Schlundt, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency an associated symptoms. Diabetes Care 1995; 18:517-22.

III. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-86.

IV. International Hypoglycemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017; 40:155-7.

V. Danne T, Nimri R, Battelino R, Bergenstal RM. International Consensus on Use of CGM. Diabetes Care 2017; 40:1631-1640.

VI. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36:1384-95.

VII. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2013; 369:362-72.

VIII. Strachan M. Frequency, causes and risk factors for hypoglycaemia in type 1 diabetes. In: Frier B, Fisher M eds, Hypoglycaemia in clinical diabetes. 2nd ed. Chichester: Hohn Wiley & Sons Ltd; 2007:48-81.

IX. Pedersen-Bjergaard U, Pramming S, Heller S, Wallace TM, Rasmussen AK, Jorgensen HV, et al. Severe hypoglycaemia in 1,076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 2004; 20:479-86.

X. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Hohnsen K, Thorsteinsson B. Prospective and retrospective recording of severe hypoglycaemia, and assessment of hypoglycaemia awareness in insulin-treated type 2 Diabetes. Diabet Med 2009; 26:1306-8.

XI. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med 1991; 8:217-22.

XII. Jorgensen H. Pedresen-Bjergaard U, Rasmussen A, Borch-Johnsen K. The impact of severe hypoglycaemia and impaired awareness of hypoglycemia on relatives of patients with type 1 diabetes. Diabetes Care 2003; 26:1106-9.

XIII. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes. Effects of treatment modalities and their duration. Diabetologia 2007; 50:1140-7.

XIV. Hepburn DA, Deary JJ, Frier B, Patrick AW, Quinn JD, Fisher M. Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM factor-analysis approach. Diabetes Care 1991; 14(11):949-57.

XV. Cox D, Goder-Frederick L, Antoum B, Cryer P, Clarke W. Perceived symptoms in the recognition of hypoglycemia. Diabetes Care 1993; 16:519-27.

XVI. Bremer J, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009; 32:1513-7.

XVII. Brierley E, Broughton D, James O, Alberti K. Reduced awareness of hypoglcaemia in the elderly despite an intact counter-regulatory response. QJM 1995; 88:439-45.

XVIII. Matyka K, Evans M, Lomas J, et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997; 20:135-41.

XIX. Murata G, Duckworth W, Shah J, et al. Factors affecting hypoglycaemia awareness in insulin-treated type 2 diabetes: The Diabetes Outcomes in Veterans Study (DOVES). Diabetes Res Clin Pract 2004; 65:61-7.

XX. Martin-Timón I, Cañizo-Gómez FJ. Mechanism of hypoglycemia unawareness and implications in diabetic patients. World J Diabetes 2015; 6(7):912-926.

XXI. Stephenson JM, Kempler P, Perin PC, Fuller JH. Is autonomic neuropathy a risk factor for severe hypoglycaemia? The EURODIAB IDDM Complications Study. Diabetologia 1996 Nov; 39(11):1372-6.

XXII. Yale JF, Paty B, Senior PA. Hypoglycemia. Can J Diabetes; 2018,42:S104-S108.

XXIII. Martin-Timón I, Cañizo-Gómez FJ. Mechanism of hypoglycemia unawareness and implications in diabetic patients. World J Diabetes 2015; 6(7):912-926.

XXIV. Cryer PE. Mechanism of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 2005; 54:3592-3601.

XXV. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006 May; 55(5):1463-9.

XXVI. Bakatselos SO. Hypoglycemia unawareness. Diabetes Res Clin Pract 2011; 93: S92-S96.

XXVII. Taborsky GJ. The physiology of glucagon. J Diabetes SCi Technol 2010; 4:1338-1344.

XXVIII. Mc Crimmon R. The mechanisms that underlie glucose sensing during hipoglycaemia in diabetes. Diabet Med 2008; 25:513-522.

XXIX. Mokan M, Mitrakou A, Veneman T, et al. Hypoglycemia unawareness in IDDM. Diabetes Care 1994; 43:1426-1434.

XXX. Lucidi P, Porcellati F, Bolli GB, et al. Prevention and management of severe hypoglycemia and hypoglycemia unawareness: incorporating sensor technology. Curr Diab Rep 2018; 18 (10):1-10.

XXXI. Fanelli C, Pampanelli S, Epifano L, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 1994; 37: 1265-1276.

XXXII. Rooijackers HMM, Wiegers EC, Tack CJ, et al. Brain glucose metabolism during hypoglycemia in type 1 diabetes: insights from functional and metabolic neuroimaging studies. Cell Mol Life Sci 2016; 73:705-122.

XXXIII. Mc Crimmon R. Glucose sensing during hypoglycemia: lessons from the lab. Diabetes Care 2009; 32:1357-1363.

XXXIV. Dunn JT, Cranston I, Marsden PK, et al. Attenuation of amygdala and frontal cortical responses to low blood glucose concentration in asymptomatic hypoglycemia in type 1 diabetes: a new player in hypoglycemia unawareness? Diabetes 2007; 56:2766-2773.

XXXV. Choi I-Y, Seaquist ER, Gruetter R. Effect of hypoglycemia on brain glycogen metabolism in vivo. J Neurosci Res 2003; 72:25-32.

XXXVI. Saez I, Duran J, Sinadinos C, et al. Neurons have an active glycogen metabolism that contributes to tolerance to hypoxia. J Cerb Blood Flow Metab 2014; 34:945-955.

XXXVII. Martín-Timón I, Del Cañizo-Gómez FJ. Mechanisms of hypoglycemia unawareness and implications in diabetic patients. World Diabetes Sci Technol 2010; 4:562-570.

XXXVIII. Giorda CB, Ozzello A, Gentile S, et al. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. Acta Diabetol 2015; 52:845-853.

XXXIX. Frier BM. Hypoglyceamia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol 2014; 10:711-722.

XL. Graveling AJ, Frier BM. The risks of nocturnal hypoglycaemia in insulin-treated diabetes. Diabetes Res Clin Pract 2017; 133:30-39.

XLI. Schouwenberg BJ, Coenen MJ, Paterson AD, et al. Genetic determinants of impaired awareness of hypoglycemia in type 1 diabetes. Pharmacogenet Genomics 2017; 27:323-328.

XLII. Segel S, Fanelli C, Dence C, Markham J, Videen TO, Paramore DS, et al. Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes 2001; 50:1911-7.

XLIII. Cranston I, Reed L, Marsden P, Amiel S. Changes in regional brain (18)F-fluorodeoxyglucose uptake at hypoglycemia in type 1 diabetic men associated with hypoglycemia unawareness and counter-regulatory failure. Diabetes 2001; 50:2329-36.

XLIV. Arbelaez A, Powers W, Videen T, Price J, Cryer P. Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure. Diabetes 2008; 57:470-5.

XLV. Dunn J, Cranston I, Marsden P, Amiel S, Reed L. Attenuation of amygdala and frontal cortical responses to low blood glucose concentration in asymptomatic hypoglycemia in type 1 diabetes: a new player in hypoglycemia unawareness? Diabetes 2007; 56:2766-73.

XLVI. Mokan A, Mitrakou A, Veneman T, Ryan C, Korytkowski M. Cryer P, et al. Hypoglycemia unawereness in IDDM: Diabetes Care 1994; 17:1397-403.

XLVII. Schwartz N, Clutter W, Shah S, Cryer P. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 1987; 79:777-81.

XLVIII. Gold A, Mac Leod K, Frier B. Frequency of severe hypoglcyemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17:697-703.

XLIX. Geddes J, Wright R, Zammit N, Deary I, Frier B. An evaluation of methods of assessing impaired awareness of hypoglycemia in type 1 diabetes. Diabetes Care 2007; 30:1868-70.

L. Clarke W, Cox D, Gonder-Frederick L, Julian K, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995; 18:517-22.

LI. Janssen M, Snoek F, Heine R. Assessing impaired hypoglycemia awareness in type 1 diabetes: agreemet of self-report but not of field study data with the autonomic symptom threshold during experimental hypoglycemia. Diabetes Care 2000; 23:529-32.

LII. Jansá M, Giménez M, Salmero M, Vidal M, Conget I, Galindo M, Levy I, Esmatíes E. Validación en lengua castellana del cuestionario de percepción de hipoglucemia Clarke. Av Diab 2011; 27:24-25.

LIII. Chico A, Vidal-Rios P, Subirá M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003; 26(2):1153-1157.

LIV. Weber KK, et al. High frequency of unrecognized hypoglycemias in patients with Type 2 diabetes is discovered by continuous glucose monitoring. Exp Clin Endocrinol Diabetes 2007; 115:491-494.

LV. Mc Coy RG, Van Houten HK, Ziegenfuss JY, et al. Increase mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012; 35:1897-1901.

LVI. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363:1410-1418.

LVII. Lu CL, Shen HN, Hu SC, et al. A population-based study of all-cause mortality and cardiovascular disease in association with prior history of hypoglycemia among patients with type 1 diabetes. Diabetes Care 2016; 39:1571-1578.

LVIII. Gogitidze Joy N, Hedrington MS, Briscoe VJ, et al. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care 2010; 33:1529-1535.

LIX. Anrte MT, Carreira M, Machado A, et al. Identification of risk factors for suffering fear of hypoglycemia in type 1 diabetes mellitus patients. Scand J Psychol 2014; 55:554-557.

LX. Schnell O, Erbach M. Impact of a reduced error range of SMBG in insulin-treated patients in Germany. J Diabetes Sci Technol 2014; 8:479-482.

LXI. Szadkowska A, Czyzewska K, Pietrzak I, et al. Hypoglycaemia unawareness in patients with type 1 diabetes. Pediatr Endocrinol Diabetes Metab 2018; 24(3):126-134.

LXII. Gold A, Pearson D. Hypoglycaemia in pregnancy. In: Frier B, Fisher M Eds. Hipoglycaemia in clinical diabetes. 2nd ed. Chichester: John Wiley & Sons Ltd; 2007:217-237.

LXIII. Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301:1565-1572.

LXIV. Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive funtion and risk of severe hupoglycemia in type 2 diabetes: post hoc epidemiologic analisys of the ACCORD trial Diabetes Care 2012; 35:787-793.

LXV. Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU, et al. Cognitive function is disrupted by both hypo-and hyperglycemia in school-aged children with type 1 diabetes: a field study. Diabetes Care 2009; 32:1001-1006.

LXVI. Martyn-Nemeth P, Farabi SS, Mihailescu D, et al. Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for prevention - a review. J Diabetes and Its Complications 2016; 30:167-177.

LXVII. Sakane N, Kotani K, Tsuzaki K, et al. Fear of hypoglycemia and its determinants in insulin-treated patients with type 2 diabetes mellitus. J Diabetes Investig 2015; 6:567-570.

LXVIII. Potter J, Clarke P, Gale E, et al. Insulin-induced hypoglyceaemia in an accident and emergency department: the tip of an iceberg? BMJ (Clin Res Ed) 1982; 285:1180-2.

LXIX. Kerr D, Macdonald I, Heller S, et al. Alcohol causes hypoglycaemic unawereness in healthy volunteers and patients with type 1 (insulin-dependent) diabetes. Diabetologia 1990; 33:216-21.

LXX. Robinson A, Parkin H Macdonald I, et al. Physiological response to postural change during mild hypoglycaemia in patients with IDDM. Diabetologia 1004; 37:1241-1250.

LXXI. Banarer S, Cryer P. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. Diabetes 2003, 52:1195-203.

LXXII. Jones T, Porter P, Sherwin R, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338:1657-62.

LXXIII. Scheltes B, Jauch-haraK, Gais S, et al. Defective awakening response to nocturnal hypoglycemia in patients with type 1 diabetes mellitus. PLos Med 2007; 4(2):e69.

LXXIV. Cox D, Gonder-Frederick L, Kovatchev B, et al. Progressive hypoglycemia´s impact in driving simulation performance. Occurrence, awareness and correction. Diabetes Care 2000; 23:163-70.

LXXV. Pohl J, Frenzel G, Kerner W, et al. Acute stress modulates symptom awareness and hormonal counterregulation during insulin-induced hypoglycemia in healthy individuals. Int J Behav Med 1995; 5:89-105.

LXXVI. Jacobson AM, Mesen G, Ryan CM, Silvers N, Cleary P, Waberski B, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356:1842-52.

LXXVII. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV, et al. Hipoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301:1565-1572.

LXXVIII. Hepburn D, Patrick A, Brash H, Thomson I, Frier B. Hipoglycemia unawareness in type 1 diabetes: a lower plasma glucose is required to stimulate sympatho-adrenal activation. Diabet Med 1991; 8:934-45.

LXXIX. Gold A, Mac Leod K, Deary I, Frier B. Hypoglycemia-induced cognitive dysfunction in diabetes mellitus: effect of hypoglycemia unawareness. Physiol Behav 1995; 58:501-11.

LXXX. Reno CM, Litvin M, Clark AL, Fisher SJ. Defective counterregulation and hypoglycemia unawareness in diabetes: mechanisms and emerging treatments. Endocrinol Metab Clin North Am 2013; 42(1):15-38.

LXXXI. Quílez Llopiz P, Reig García-Galbis M. Control glucémico a través del ejercicio físico en pacientes con diabetes mellitus tipo 2. Revisión sistemática. Nutr Hosp. 2015; 31(4):1465-1472.

LXXXII. Mao Y, Wen S, Zhou M, Zhu S, Zhou L. The hypoglycemia associated autonomic failure triggered by exercise in patients with "brittle" diabetes and the strategy for prevention. Endocr J 2019; 66(9):753-762.

LXXXIII. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND Randomized Clinical Trial. JAMA 2017; 317(4):371-378.

LXXXIV. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016; 388(10057):2254-2263.

LXXXV. Šoupal J, Petruželková L, Grunberger G, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR Study. Diabetes Care 2020; 43(1):37-43.

LXXXVI. Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet 2018; 391(10128):1367-1377.

LXXXVII. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369(3):224-232.

LXXXVIII. Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol 2017; 5(7): 501-512.

LXXXIX. Beato-Víbora PI, Gallego-Gamero F, Lázaro-Martín L, Romero Pérez Ma del Mar Arroyo-Díez FJ. Prospective analysis of the impact of commercialized hybrid closed-loop system on glycaemic control, glycaemic variability and patient-related outcomes in children and adults: a focus on superiority over predictive low glucose suspend technology. Diabetes Technol Ther 2020 Dec; 22(12):912-919. DOI: 10.1089/dia.2019.0400.

XC. Petrovski G, Al Khalaf F, Campbel J, Umer F, Almajaly D, Hamdan N, Hussain K. One year experience of hybrid closed loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes Acta Diabetologica 2021 Feb; 58(2):207-213.

XCI. Litwak LE, Querzoli I, Musso C, Dain A, Houssay S, Proietti A, Costa Gil JE. Monitoreo continuo de glucosa. Utilidad e indicaciones. MEDICINA (Buenos Aires) 2019; 79: 44-52.

XCII. Rickels MR,Robertson RP. Pancreatic islet transpantation in humans: Recent progress and future directions. Endocrine Reviews 2019; 40(2):631-668.




DOI: http://dx.doi.org/10.47196/diab.v55i2.473

Copyright (c) 2021 Sociedad Argentina de Diabetes Asociación Civil

ADVERTISEMENT
ADVERTISEMENT